One clinical-data leak can mean hundreds of millions in losses and years of delay.
As the BD leader or clinical project director of a pharmaceutical company, every piece of clinical trial data and every License-out transaction in your hands is a race against time and regulation. The leakage of Phase III clinical data may allow competitors to rush to apply, and confusion in the version of the registration document may lead to delays in approval of NMPA/FDA. Data security during License-out presentation is also related to the success or failure of hundreds of millions of dollars in transactions.
Linxy has created a compliance data management platform covering the entire "clinical-registration-transaction" link for the pharmaceutical industry. It's not about "storing" files, but protecting the security of everything from patient privacy to business transactions.
When every dataset represents real patients and real capital, the safety bar has no elasticity.
Clinical data involves patient privacy under GCP/HIPAA. Encryption, authorization, and secure transfer get exponentially harder across sites, CROs, and borders. One gap can mean rejected data and pipeline delay — not just fines.
CMC, nonclinical, and clinical reports must stay version-consistent across NMPA/FDA/EMA review. One conflict can trigger deficiency letters and months or years of delay.
License-out The transaction needs to show the most core data to potential partners—the efficacy data, safety results, and mechanism of action of Phase III clinical trials. Showing too little will fail to stimulate interest, showing too much in depth will risk the data being used maliciously. In deal negotiations worth hundreds of millions or even billions of dollars, the data display strategy is the transaction strategy - so a platform that can fully demonstrate value and have absolute control over the data is needed.
Automate patient de-identification and restrict access down to CRF sets and experiment cohorts. Cross-site and CRO collaboration stays inside a compliance frame with audit-ready logs.
Centralize CMC, nonclinical, and clinical reports with revision-level version control and change highlighting — so submissions stay current and consistent.
Core clinical data are displayed online without downloading, and dynamic watermarks cover every screen. Potential partners can have in-depth online viewing of efficacy data and safety assessments, but “take away” any of the original data—the value of the display and control of the data are online at the same time and belong to everyone at the same time.
Different CROs and CDMOs get isolated spaces by indication or process. Vendor A never sees Vendor B — outsourcing without cross-contamination risk.
From GCP compliance in China to 21 CFR Part 11 electronic records requirements in the U.S. FDA to data protection standards in Europe EMA - Linxy’s compliance framework covers major regulatory standards around the world. Just focus on drug research and development, and the underlying framework for compliance is already in place.
Privacy is non-negotiable. Masking, authorization, encrypted transfer, and secure storage protect clinical data across its full lifecycle.
From a non-confidential overview of first contact to in-depth due diligence of core data exposure - Linxy's layered authorization mechanism precisely controls the extent of information exposure at every License-out negotiation stage. The more you show, the more you protect – security and efficiency are never a zero-sum game.
Leave your contact information and our advisor will discuss a trial or demo with you.